PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19563513-4	2009	Furthermore, when CML cells were treated with imatinib there was a 55% and 20% reduction of p210(BCR-ABL1) and p145(ABL1) binding to pericentrin, respectively.	Imatinib Mesylate	46-54	POM121 transmembrane nucleoporin	Homo sapiens	111-115